This information was from globalhealth.

This information was from globalhealth.org with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report search the archives and sign up for email delivery at global health. – Rotavirus – ‘one of the main causes of severe gastroenteritis, including vomiting and diarrhea in infants and young children ‘ – ‘an estimated 1,600 children killed under the age of 5 every day, mostly in Africa and Asia,’Reuters writes (MacInnis Reuters.

The number of people who have their HIV status drastically increase in the global fight against HIV / AIDS moving forward , white U.S. Ambassador Randall Tobias, head of the. State Department Office of the U.S. Global AIDS Coordinator, writes in a Miami Herald opinion piece. To the President Emergency Plan for AIDS Relief Five-year goal of support to achieve antiretroviral treatment for two million HIV-positive people in 15 severely affected countries, the government estimates that have 100 million people HIV test requirements, says Tobias by that only people who know they are HIV-positive medical treatment and are able to steps for prevention.The case of dialysis patients trying, named EMERALD 1 and EMERALD 2, are evaluating the safety and efficacy of Hematide and its ability Which to keep in a corrected area when patients from epoetin alfa or epoetin beta to Hematide be switched.

‘The completion enrollment in our first Phase 3 study on Hematide is significant and moved us closer toward our ultimate goal, once-monthly alternative treatment to many people with anemia with chronic renal impairment. Its capacity to the completion of Enrolment aim to the other three phase to 3 clinical studies our pivotal program by the end of of 2008. We put this to composite results of, with data from all four trials in spring of 2013. Think line with our previous forecast we anticipate submit a New Drug Application to Hematide in chronic renal failure in 2013 if everything goes as scheduled. ‘.. Affymax announced that enrolling of four phase of four phase clinical three study of its lead experimental therapy, Hematide for treating for the treatment of anemia patients chronic renal.